ClinicalTrials.gg
Not yet recruitingNCT07949162CSSİGNUpdated Nov 19, 2026

Ultrasound Sliding Sign for Predicting Abdominal Adhesions Before Repeat Cesarean Delivery

An observational study in Tissue Adhesions, Cesarean Section, Repeat and Intra-abdominal Adhesions, sponsored by Ankara City Hospital Bilkent. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 46 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Ankara City Hospital Bilkent · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years to 46 Years
Sex
Female
01

Study summary

This study evaluates how accurately a simple ultrasound test, the sliding sign, predicts intra-abdominal adhesions before a repeat cesarean delivery. Adhesions are bands of scar tissue that can form between the uterus, the bladder and the abdominal wall after a cesarean delivery. Adhesions can lengthen the next operation, delay delivery of the baby, increase bleeding and raise the risk of injury to the bladder or bowel.

The sliding sign is checked by placing a standard ultrasound probe on the abdomen while the woman breathes deeply. Free sliding of the uterus under the abdominal wall suggests that adhesions are unlikely; absence of sliding suggests that adhesions are present. The test takes 2 to 3 minutes, is painless, has no known risk to the mother or the baby, and adds no cost.

Pregnant women with at least one previous cesarean delivery who are scheduled for a planned repeat cesarean delivery at Ankara Bilkent City Hospital are invited to take part. The sliding sign is checked within 2 hours before surgery. During the operation, a surgeon who does not know the ultrasound result grades any adhesions on a standard four-grade scale, and the ultrasound result is compared with these surgical findings. The study also compares operative times, blood loss and complications between women with and without free sliding of the uterus, and examines whether the test performs differently after one previous cesarean delivery than after two or more. Taking part does not change the planned surgery or any other aspect of care.

Read the detailed description

Background:

Intra-abdominal adhesions are common after cesarean delivery, and their frequency and severity increase with each additional cesarean delivery. Adhesions prolong the interval from skin incision to delivery of the fetus and the total operative time, increase blood loss, and raise the risk of bladder and bowel injury. Preoperative prediction of the adhesion burden could support planning of the surgical team, estimation of operative time, blood preparation and patient counseling. The sliding sign is a simple transabdominal ultrasound test that shows whether the anterior uterine wall moves freely against the anterior abdominal wall during breathing. It requires no additional equipment or cost and takes 2 to 3 minutes. Its previously reported sensitivity is moderate (approximately 56%) and its specificity is high (approximately 95%). Test performance according to the number of previous cesarean deliveries, and the relationship between the test result and surgical outcomes, have not been well characterized.

Design:

Single-center, prospective, observational (non-interventional) diagnostic accuracy study at the Department of Obstetrics and Gynecology, Ankara Bilkent City Hospital, reported according to the STARD 2015 (Standards for Reporting of Diagnostic Accuracy Studies) guideline. Eligible women are invited consecutively.

Index test (sliding sign):

Within 2 hours before surgery, in the preoperative preparation room, transabdominal ultrasound is performed with a convex probe. Following the original technique, the movement of the anterior uterine wall relative to the anterior abdominal wall is observed while the participant breathes deeply, with the probe at the level of the umbilicus, lateral to the midsagittal plane. The suprapubic, right paramedian and left paramedian regions are also assessed separately, and the result for each region is recorded.

  • Negative sliding sign (test positive, adhesions expected): absence of sliding in at least one assessed region
  • Positive sliding sign (test negative): sliding in all assessed regions
  • Non-evaluable: image quality inadequate for assessment. Non-evaluable examinations are not excluded from the study; their proportion is reported and they are addressed in a sensitivity analysis.

Reference standard (intraoperative adhesion grading):

Immediately after entry into the abdominal cavity and before any adhesiolysis, the operating surgeon grades adhesions on a four-grade cesarean-specific scale:

  • Grade 0: no adhesions
  • Grade 1: thin, filmy adhesions easily separated by blunt dissection
  • Grade 2: moderate or thick adhesions requiring sharp dissection
  • Grade 3: extensive, dense adhesions with no free space between the uterus and the anterior abdominal wall Significant adhesions (primary target condition) are pre-defined as Grade 2 or 3. Grade 3 alone is analyzed as a secondary target condition. Adhesion location is recorded with the same anatomical scheme as the index test (midline/suprapubic, right paramedian, left paramedian), together with uterus-bladder and omental adhesions.

Blinding:

The ultrasound examiner is not the surgeon performing the operation. The operating surgeon is unaware of the ultrasound result, and the ultrasound examiner does not learn the surgical findings until the operation is completed. The ultrasound and surgical forms are completed separately, sealed in envelopes and matched at data entry.

Standardization and interobserver agreement:

Before the study begins, both assessors complete a standardization session on the technique and the grading definitions. In the first 30 participants, two investigators assess the sliding sign independently, within 15 minutes of each other.

Data collection:

Sociodemographic data, surgical history, operative times, blood loss, complications, laboratory values and newborn data are obtained from routine clinical care and from operative and anesthesia records. The only study-specific procedures are the 2-to-3-minute preoperative sliding sign assessment and the standardized recording of adhesions. Surgical technique, the decision for surgery, the timing of surgery and all other aspects of care are not changed by the study. Women whose operation becomes an emergency cesarean delivery after the ultrasound examination are excluded from the analysis and reported in the participant flow diagram. Participants may withdraw at any time without any effect on their care; on request, their data are removed from the analysis and destroyed.

Sample size:

Assuming a 30% prevalence of significant adhesions (Grade 2 or 3) and an expected sensitivity of 56%, 66 women with significant adhesions are required to estimate sensitivity with an absolute precision of ±12% (alpha 0.05), corresponding to 220 participants. This sample also provides more than the 73 women without significant adhesions required to estimate an expected specificity of 95% with a precision of ±5%. Allowing 10% for non-evaluable examinations and data loss, the target enrollment is 240 women, with 220 participants expected to be analyzable.

Statistical analysis:

  • Sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios and overall accuracy, each with a 95% confidence interval (Wilson method), presented in a 2x2 table
  • Primary analysis excluding non-evaluable examinations; sensitivity analysis counting all non-evaluable examinations first as test positive and then as test negative
  • Stratified analysis by number of previous cesarean deliveries (one versus two or more), with sensitivity and specificity compared between strata using the chi-square test and the adhesion prevalence reported for each stratum
  • Exploratory subgroup analysis by body mass index (below 30 versus 30 kg/m² or above), without confirmatory interpretation
  • Suprapubic-only versus three-region assessment: agreement by kappa coefficient and difference in accuracy by McNemar's test; agreement between the ultrasound-identified region and the surgical location of adhesions by kappa coefficient
  • Surgical outcomes compared between women with a negative and a positive sliding sign using Student's t test or the Mann-Whitney U test, according to distribution, and the chi-square or Fisher's exact test for complication rates
  • Multivariable logistic regression for independent predictors of significant adhesions, limited to four variables (sliding sign, number of previous cesarean deliveries, peritoneal closure at the previous cesarean delivery, body mass index), reported as odds ratios with 95% confidence intervals
  • Interobserver agreement in the first 30 participants by kappa coefficient with 95% confidence interval
  • Two-sided p \< 0.05 considered statistically significant; analyses performed with SPSS (IBM Corp., USA)
02

Conditions studied

  • Tissue Adhesions
  • Cesarean Section, Repeat
  • Intra-abdominal Adhesions

Browse trials for

Keywords

  • Sliding sign
  • Transabdominal ultrasonography
  • Repeat cesarean delivery
  • Previous cesarean delivery
03

In context

Tissue Adhesions

121 studies on the registry are indexed under Tissue Adhesions; 15 are open to participants now.

This study's planned enrollment of 240 is above the median of 130 across 32 observational studies indexed under Tissue Adhesions.

Browse Tissue Adhesions studies →

Lead sponsor

Ankara City Hospital Bilkent is the lead sponsor of 450 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 46 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women aged 18 to 45 years with at least one previous cesarean delivery who are scheduled for elective repeat cesarean delivery at 37 weeks of gestation or later at the Department of Obstetrics and Gynecology, Ankara Bilkent City Hospital, Ankara, Türkiye. Eligible women are invited consecutively during the study period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 45 years
  • At least one previous cesarean delivery
  • Elective repeat cesarean delivery scheduled at 37 weeks of gestation or later
  • Written

Exclusion criteria

Exclusion Criteria:

  • Cesarean delivery performed under emergency conditions
  • In labor
  • Placenta previa
  • Suspected placenta accreta spectrum
  • History of major abdominal surgery other than cesarean delivery
  • Reference standard assessment not possible because the operation is performed under conditions different from those planned
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • One Previous Cesarean Delivery

    Pregnant women with one previous cesarean delivery who are scheduled for elective repeat cesarean delivery at 37 weeks of gestation or later. All participants undergo a preoperative transabdominal ultrasound sliding sign assessment and intraoperative adhesion grading by a surgeon blinded to the ultrasound result. Surgical management is not changed by the study.

    Diagnostic Test: Transabdominal Ultrasound Sliding Sign Assessment

  • Two or More Previous Cesarean Deliveries

    Pregnant women with two or more previous cesarean deliveries who are scheduled for elective repeat cesarean delivery at 37 weeks of gestation or later. All participants undergo a preoperative transabdominal ultrasound sliding sign assessment and intraoperative adhesion grading by a surgeon blinded to the ultrasound result. Surgical management is not changed by the study.

    Diagnostic Test: Transabdominal Ultrasound Sliding Sign Assessment

Interventions

  • Diagnostic testTransabdominal Ultrasound Sliding Sign Assessment

    Transabdominal ultrasound examination with a convex probe, performed in the preoperative preparation room within 2 hours before surgery. Following the original technique, the movement of the anterior uterine wall relative to the anterior abdominal wall is observed while the participant breathes deeply, with the probe at the level of the umbilicus, lateral to the midsagittal plane. The suprapubic, right paramedian and left paramedian regions are also assessed separately. Absence of sliding in at least one assessed region is classified as a negative sliding sign (test positive, adhesions expected); sliding in all assessed regions is classified as a positive sliding sign (test negative). Examinations with inadequate image quality are classified as non-evaluable. The examination takes 2 to 3 minutes and does not change clinical management.

    Also known as: Sliding sign, Uterine sliding sign

06

What researchers measure

Primary outcomes

  1. Sensitivity of the Sliding Sign for Significant Intra-Abdominal Adhesions

    Proportion of participants with significant adhesions (Grade 2 or 3 on a four-grade intraoperative scale) who have a negative sliding sign (absence of sliding in at least one assessed region on preoperative transabdominal ultrasound). Adhesion grades: 0, none; 1, filmy adhesions separated by blunt dissection; 2, moderate or thick adhesions requiring sharp dissection; 3, dense, extensive adhesions with no free space between the uterus and the anterior abdominal wall. Adhesions are graded by the operating surgeon, blinded to the ultrasound result, immediately after entry into the abdominal cavity and before adhesiolysis. Reported as a percentage with 95% confidence interval (Wilson method), for all participants and for each group. Non-evaluable examinations are excluded from this analysis.

    Time frame: Day of surgery: ultrasound within 2 hours before surgery; adhesion grading at entry into the abdominal cavity

  2. Specificity of the Sliding Sign for Significant Intra-Abdominal Adhesions (Grade 2-3)

    Proportion of participants without significant adhesions (Grade 0 or 1 on the four-grade intraoperative scale) who have a positive sliding sign (sliding in all assessed regions on preoperative transabdominal ultrasound). Adhesions are graded by the operating surgeon, blinded to the ultrasound result, immediately after entry into the abdominal cavity and before adhesiolysis. Reported as a percentage with 95% confidence interval (Wilson method), for all participants and for each group. Non-evaluable examinations are excluded from this analysis.

    Time frame: Day of surgery: ultrasound within 2 hours before surgery; adhesion grading at entry into the abdominal cavity

Secondary outcomes

  1. Positive Predictive Value of the Sliding Sign for Significant Adhesions (Grade 2-3)

    Proportion of participants with a negative sliding sign (absence of sliding in at least one assessed region) who have significant adhesions (Grade 2 or 3) at surgery. Reported as a percentage with 95% confidence interval (Wilson method), for all participants and for each group.

    Time frame: Day of surgery: ultrasound within 2 hours before surgery; adhesion grading at entry into the abdominal cavity

  2. Positive Likelihood Ratio of the Sliding Sign for Significant Adhesions (Grade 2-3)

    Sensitivity divided by (1 minus specificity) of the sliding sign for significant adhesions (Grade 2 or 3) at surgery, reported with 95% confidence interval, for all participants and for each group.

    Time frame: Day of surgery: ultrasound within 2 hours before surgery; adhesion grading at entry into the abdominal cavity

07

Study locations

1 site
08

References and documents

Publications

  • Tulandi T, Agdi M, Zarei A, Miner L, Sikirica V. Adhesion development and morbidity after repeat cesarean delivery. Am J Obstet Gynecol. 2009 Jul;201(1):56.e1-6. doi: 10.1016/j.ajog.2009.04.039. PubMed 19576375 ↗
  • Shafti V, Azarboo A, Ghaemi M, Gargari OK, Madineh E. Prediction of intraperitoneal adhesions in repeated cesarean sections: A Systematic review and Meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2023 Aug;287:97-108. doi: 10.1016/j.ejogrb.2023.05.039. Epub 2023 Jun 1. PubMed 37302234 ↗
  • Drukker L, Sela HY, Reichman O, Rabinowitz R, Samueloff A, Shen O. Sliding Sign for Intra-abdominal Adhesion Prediction Before Repeat Cesarean Delivery. Obstet Gynecol. 2018 Mar;131(3):529-533. doi: 10.1097/AOG.0000000000002480. PubMed 29420398 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared, in accordance with the Turkish Personal Data Protection Law (Law No. 6698) and the scope of the informed consent approved by the ethics committee. Aggregate results will be reported in a peer-reviewed publication.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Mar 10, 2027
CompletionEst.
Apr 10, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949162
Responsible party
Ayşenur Türe (Specialist, Ankara City Hospital Bilkent) — Principal investigator
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Mar 10, 2027 (estimated)
Completion
Apr 10, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion